Paradigm Biocapital Advisors LP: ERASCA INC (ERAS): Quarterly 13F Position History
As of Q1 2026, Paradigm Biocapital Advisors LP reported 10,392,702 shares of ERASCA INC (ERAS), worth $168.2M and representing 3.4% of its 13F equity book. Quarter-over-quarter share count change: 3,766,393 (-26.6%) . The position first appeared in Q2 2024 and has been disclosed across 8 13F-HR filings in Pactolio's tracked window.
- 10,392,702Shares Held (Latest Filing)
- $168.2MReported Market Value (Latest Filing)
- 3.4%Portfolio Weight (% of 13F Equity Book)
- 3,766,393Quarter-over-Quarter Share Change
- +$115.5MQuarter-over-Quarter Value Change
- 14,159,095Peak Reported Shares (Historical)
Quarterly 13F-HR Disclosure History Source: SEC 13F-HR filings, 8 quarter s
| Quarter | Shares | QoQ Share Change | Share Change (%) | Market Value | Weight | Implied Price |
|---|---|---|---|---|---|---|
| Q1 2026 | 10,392,702 | 3,766,393 | -26.6% | $168.2M | 3.4% | $16.2 |
| Q4 2025 | 14,159,095 | +599,078 | +4.4% | $52.7M | 1.4% | $3.7 |
| Q3 2025 | 13,560,017 | +1,652,835 | +13.9% | $29.6M | 0.9% | $2.2 |
| Q2 2025 | 11,907,182 | +1,104,828 | +10.2% | $15.1M | 0.6% | $1.3 |
| Q1 2025 | 10,802,354 | +50,000 | +0.5% | $14.8M | 0.7% | $1.4 |
| Q4 2024 | 10,752,354 | +84,213 | +0.8% | $27.0M | 0.9% | $2.5 |
| Q3 2024 | 10,668,141 | +3,418,141 | +47.1% | $29.1M | 1.0% | $2.7 |
| Q2 2024 | 7,250,000 | — | — | $17.1M | 0.7% | $2.4 |
Methodology & FAQ
How This Position History Is Sourced
Each row is one SEC Form 13F-HR filing disclosing this position. Share count, market value, and reported quarter are taken verbatim from the filing; portfolio weight is recomputed against the same filing's total reported equity book. Implied price-per-share is market value divided by shares — a quarter-end mark, not the manager's cost basis. See the full methodology document for the normalization rules.
When did Paradigm Biocapital Advisors LP first disclose a ERAS position in 13F-HR filings?
Paradigm Biocapital Advisors LP first reported ERASCA INC (ERAS) on its 13F-HR filing for the period ending 2024-06-30 (Q2 2024). The position has appeared on 8 reported quarters within Pactolio's tracked window.
What was Paradigm Biocapital Advisors LP's most recent quarter-over-quarter share-count change in ERAS?
Between Q4 2025 and Q1 2026, Paradigm Biocapital Advisors LP reduced its ERAS position by 3,766,393 shares (-26.6%), leaving 10,392,702 shares at a market value of $168.2M.
Does the implied price-per-share represent Paradigm Biocapital Advisors LP's cost basis in ERAS?
No. The implied price-per-share column is the 13F-HR reported market value divided by reported share count on the filing date (end of quarter). It is a quarter-end mark, not a cost basis or transaction price. Use it as a sanity check on the value column, not as an indicator of the manager's entry or exit price.